Clevidipine: A new intravenous option for the management of acute hypertension

American Journal of Health-System Pharmacy

Volumn 67, Issue 5, 2010, Pages 351-360

  Ndefo, Uche Anadu ^a   Erowele, Goldina Ikezuagu ^b   Ebiasah, Ruth ^c   Green, Wendy ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

^c HOLY CROSS HOSPITAL   (United States)

Author keywords

Clevidipine butyrate; Dosage; Drug administration routes; Half life; Hypertension; Hypotensive agents; Mechanism of action; Metabolism; Pharmacokinetics; Toxicity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CLEVIDIPINE; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; LABETALOL; NICARDIPINE; NITROPRUSSIDE SODIUM;

ACUTE KIDNEY FAILURE; ATELECTASIS; BLOOD PRESSURE REGULATION; CENTRAL VENOUS PRESSURE; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FEVER; HEADACHE; HEART AFTERLOAD; HEART ATRIUM FIBRILLATION; HEART INDEX; HEART PRELOAD; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; MEAN ARTERIAL PRESSURE; NAUSEA; PERIOPERATIVE HYPERTENSION; POSTOPERATIVE HYPERTENSION; PREOPERATIVE HYPERTENSION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; REVIEW; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VOMITING;

EID: 77949652037     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080692     Document Type: Review

References (28)

1. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:2560-72. [Erratum, JAMA. 2003; 290:197.]
2. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115:e69-171. [Erratum, Circulation. 2007; 115:e172.]
3. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. [Erratum, Chest. 2007; 132:1721.]
4. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008; 68:283-97.
5. Food and Drug Administration. Approval letter for Cleviprex (clevidipine butyrate). NDA approval letter. www.accessdata.fda.gov/drugsatfda-docs/nda/2008/ 022156s000-Approv.pdf (accessed 2009 Nov 23).
6. Singla N, Warltier DC. Treatment of acute postoperative hypertension in cardiac surgery patients: an Efficacy Study of Clevidipine Assessing its Postoperative Anti-hypertensive Effect in Cardiac Sugery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008; 107:59-67.
7. Vaidya CK, Ouellette JR. Hypertensive urgency and emergency. Hosp Physician. 2007;43(Mar):43-50.
8. Pitt B. Diversity of calcium antagonists. Clin Ther. 1997; 19:3-17.
9. Rampe D, Su CM, Yousif F et al. Calcium channel antagonists: pharmacological considerations. Br J Clin Pharmacol. 1985; 20(suppl 2):247S-254S.
10. Levy JH. Management of systemic and pulmonary hypertension. Tex Heart Inst J. 2005; 32:467-71.
11. Ericsson H, Fakt C, Höglund L et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 1999; 55:61-7.
12. Schwieler JH, Ericsson H, Lofdahn P et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999; 34:268-74.
13. Ericsson H, Fakt C, Jolin-Mellgård Å et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999; 47:531-8.
14. Soons PA, Cohen AF, Breimer DD. Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers. Eur J Clin Pharmacol. 1993; 44:113-20.
15. Bailey JM, Lu W, Levy JH et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology. 2002; 96:1086-94.
16. Ericsson H, Bredberg U, Eriksson U et al. Pharmacokinetics and arteriovenous differences in clevidipine concentration following short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000; 92:993-1001.
17. Kieler-Jensen N, Jolin-Mellgård Å, Nordlander M et al. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesth Scand. 2000; 44:186-93.
18. Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999; 8:29-37.
19. Cleviprex (clevidipine butyrate injectable emulsion) product information. Clayton, NC: The Medicines Company; 2008.
20. Benet LZ. General treatment of linear mammilary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci. 1972; 61:536-41.
21. Vuylsteke A, Milner Q, Ericsson H et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth. 2000; 85:683-9.
22. Pollack CV, Varon J, Garrison NA et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009; 53:329-38.
23. Aronson S, Dyke CM, Stierer KA et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008; 107:1110-21.
24. Levy JH, Mancao MY, Gitter R et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007; 105:918-25.
25. Zhang GJ, Dehal SS, Ho T et al. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006; 34:734-7.
26. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008; 22:596-607.
27. Powroznyk AV, Vuylsteke A, Naughton C et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 2003; 20:697-703.
28. Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health-Syst Pharm. 2004; 61:1661-75.